The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 2
The primary endpoint of the TRANSFORM-1 study was spleen volume reduction ≥35% (SVR35) at Week 24. What percentage of patients treated with navitoclax + ruxolitinib achieved the primary endpoint?
A
B
C
D
Ruxolitinib (RUX) monotherapy is currently the standard of care for patients diagnosed with myelofibrosis, with spleen volume reduction ≥35% (SVR35) at Week 24 consistently in the range of 29%–49%.1 While patients experience symptom improvement and spleen volume reduction ≥35%, limited benefit remains in key clinical outcomes.1 Navitoclax (NAV), a novel oral B-cell lymphoma-extra-large and B-cell lymphoma-2 inhibitor in combination with RUX has shown antitumor activity and clinical benefit in the recent phase II REFINE trial (NCT03222609).
At the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, Pemmaraju presented key efficacy and safety data from the phase III TRANSFORM-1 study (NCT04472598), the first randomized clinical trial investigating NAV + RUX combination compared with RUX + placebo (PBO) in patients with Janus kinase inhibitor-naïve myelofibrosis. We summarize the key points below.
Table 1. Eligibility criteria*
ECOG, European Co-operative Oncology Group; JAK, Janus kinase; MF, myelofibrosis. |
Eligibility criteria |
---|
Age ≥18 years |
ECOG performance score ≤ 2 |
Intermediate-2 or high-risk MF |
Measurable splenomegaly |
Evidence of symptoms |
No prior JAK inhibitor therapy |
Table 2. Baseline patient characteristics*
CALR, calreticulin; DIPSS+, Dynamic International Prognostic Scoring System plus; HMR, high molecular risk; JAK, Janus kinase; MPL, ; myeloproliferative leukemia virus oncogene; NAV, navitoclax; PBO, placebo; RUX, ruxolitinib; TSS, Total Symptom Score. |
||
Characteristic, % (unless otherwise stated) |
NAV + RUX (n = 125) |
RUX + PBO (n = 127) |
---|---|---|
Age, years |
70 |
69 |
Sex, male |
50 |
64 |
Number of prior lines of therapy, median (range) |
1 |
1 |
Median spleen volume, cm3 |
1,441 |
1,639 |
Median TSS |
21 |
24 |
DIPSS+ risk |
||
Intermediate-1 |
6 |
4 |
Intermediate-2 |
83 |
87 |
High-risk |
10 |
9 |
Driver mutation |
||
JAK2V617F |
65 |
62 |
CALR |
18 |
20 |
MPLW515 |
11 |
8 |
HMR mutations |
48 |
43 |
Figure 1. SVR35 response at Week 24 and at any time*
NAV, navitoclax; PBO, placebo; RUX, ruxolitinib; SVR35, spleen volume reduction ≥35%.
*Adapted from Pemmaraju.1
Figure 2. Most common AEs of any grade experienced by 30% of patients receiving NAV*
AE, adverse event; NAV, navitoclax; PBO, placebo; RUX, ruxolitinib.
*Adapted from Pemmaraju.1
This was the first randomized clinical trial investigating NAV + RUX in this setting. SVR35 at Week 24 was doubled for patients treated with combination therapy compared with RUX + PBO. AEs were manageable, mainly through dose modification. Further evaluations are ongoing to investigate overall survival and clinical responses in patient subgroups.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content